Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Insulinoma × vatalanib × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vipoma 1 Somatostatinoma 1 Insulinoma 1 Glucagonoma 1 Gastrinoma 1 Carcinoma, Islet Cell 1

Interventions

veliparib 1 vatalanib 1 pasireotide 1 Temozolomide 1 Solutions 1 Saline Solution 1 Octreotide 1 Injections 1 Capecitabine 1 Biological Therapy 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡